Tuesday, June 16, 2026 7:06 PM ET

CATALYST News

Earnings Insight

Earnings Calendar

Date Time Symbol company_name Period Metric Estimate Actual Surprise YrAgo Growth sector_industry
06/16/2026 BMO BVC BitVentures H1 2025 EPS 0.56
06/16/2026 BMO BVC BitVentures H1 2025 REV 0.00 0.00
06/16/2026 BMO TRIB Trinity Biotech Q1 2026 EPS -0.23
06/16/2026 BMO TRIB Trinity Biotech Q1 2026 REV 10.85 M
06/16/2026 BMO UXIN Uxin Q1 2026 EPS -0.05 -0.03 -66.70
06/16/2026 BMO UXIN Uxin Q1 2026 REV 155.65 M 0.00 55.21 M 181.94
06/16/2026 BMO VNCE Vince Holding Q1 2026 EPS -0.13 -0.16 -23.08 -0.37 56.80
06/16/2026 BMO VNCE Vince Holding Q1 2026 REV 63.05 M 64.04 M 1.57 57.93 M 10.53
06/16/2026 BMO WDH Waterdrop Q1 2026 EPS 0.04 0.05 -20.00
06/16/2026 BMO WDH Waterdrop Q1 2026 REV 180.09 M 0.00 103.86 M 73.39

Pre-Market Insights

Pre-Market Movers

Date Time Symbol Company Name Last Updated PrevClose Price Change Percent stockprice52wklow stockprice52wkhigh 52Wk Range company_sector company_industry Sector / Industry dailyvolume marketcap news_link Catalyst News
06/16/2026 07:05 PM CREG Smart Powerr Corp. 16-Jun 09:19 2.07 2.07 1.88 989.47 1.62 34.99 $1.62 ~ $34.99 Utilities Utilities - Renewable 320.40 4.75
06/16/2026 07:05 PM HSPT Horizon Space Acquisition II Corp. 16-Jun 09:20 8.92 9.99 6.61 195.56 3.00 14.31 $3.00 ~ $14.31 Financial Shell Companies 32.23 70.62
06/16/2026 07:04 PM AHMA Ambitions Enterprise Management Co. 16-Jun 09:20 2.69 3.33 1.40 72.54 0.76 39.50 $0.76 ~ $39.50 Consumer Cyclical Travel Services 38.86 79.96
06/16/2026 07:05 PM IVDA Iveda Solutions, Inc. 16-Jun 09:20 0.49 0.43 0.12 38.71 0.22 2.58 $0.22 ~ $2.58 Industrials Security & Protection Services 356.93 1.38 Iveda Introduces High-Precision Real-Time Location Upgrade with 10cm Accuracy and New AoA Sensors
GuruFocus | 2026-06-15 09:00:00
06/16/2026 07:05 PM NIVF NewGenIvf Group Limited 16-Jun 09:20 0.70 0.79 0.21 36.21 0.47 420.00 $0.47 ~ $420.00 Healthcare Medical Care Facilities 100.54 400.00
06/16/2026 07:05 PM CRVO CervoMed Inc. 16-Jun 09:20 4.52 3.30 0.82 33.06 2.13 13.13 $2.13 ~ $13.13 Healthcare Biotechnology 197.94 41.85
06/16/2026 07:05 PM CRE Cre8 Enterprise Limited Class A Ord 16-Jun 09:20 3.27 4.11 0.96 30.48 1.68 102.18 $1.68 ~ $102.18 Industrials Specialty Business Services 21.90 6.59
06/16/2026 07:05 PM GDHG Golden Heaven Group Holdings Ltd. 16-Jun 09:20 1.85 2.13 0.43 25.29 1.41 25.80 $1.41 ~ $25.80 Consumer Cyclical Leisure 16.38 4.55
06/16/2026 07:05 PM BEEM Beam Global 16-Jun 09:20 1.32 1.46 0.28 23.73 1.10 4.04 $1.10 ~ $4.04 Technology Solar 55.05 24.00 Beam Stock Rises After European Patent Office Grants Battery Thermal Management Patent
Benzinga | 2026-06-16 08:00:56
06/16/2026 07:05 PM RXT Rackspace Technology, Inc. 16-Jun 09:20 6.21 7.19 1.27 21.45 0.39 7.65 $0.39 ~ $7.65 Technology Software - Infrastructure 81.62 1.55 Why Rackspace Rallied Today
The Motley Fool | 2026-06-16 16:14:39
Rackspace Technology, Inc. (RXT) Discusses Phased Deployment Agreement for AMD AI Compute and GPU-as-a-Service Collaboration Transcript
Seeking Alpha | 2026-06-16 11:02:09
This little-known AI stock has beaten Micron and Arm this year, and now it's extending its lead
Market Watch | 2026-06-16 10:39:00
A Rackspace Technology Insider Sold Nearly 34,000 Shares. Here's What That Means for Investors.
The Motley Fool | 2026-06-15 12:01:46

Bio-Pharm Insight

FDA Calendar

Date Symbol Company time event_type Drug Drug Details Status Catalyst target_date_from target_date_to Catalyst Summary Source
05/19/2026 CGEM Cullinan Therapeutics 07:00 AM FDA Decision CLN-049 CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia Phase 1 Orphan Drug Designation 05/19/2026 05/19/2026 Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
09/05/2025 CERO CERo Therapeutics Holdings 08:00 AM FDA Decision CER-1236 For the treatment of Acute Myeloid Leukemia (AML) Phase 2 Fast Track Designation 09/05/2025 09/05/2025
09/04/2025 AMRX Amneal Pharmaceuticals 04:01 PM FDA Decision Risperdal Consta An extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, Approved FDA Approval 09/04/2025 09/04/2025
09/04/2025 LLY Eli Lilly and Company 07:45 AM FDA Decision Olomorasib + KEYTRUDA (pembrolizumab) For the first-line treatment of patients with unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 expression = 50% SUNRAY-01 Phase 3 Breakthrough Therapy designation 09/04/2025 09/04/2025
07/02/2025 TIL Instil Bio 06:00 AM FDA Decision AXN-2510 A PD-L1xVEGF Bispecific Antibody, for the treatment of Relapsed/Refractory Solid Tumors Phase 1 Investigational New Drug (IND) 11/30/-0001 11/30/-0001 Instil Bio, Inc. (TIL) announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application for AXN-2510. Instil Bio plans to initiate a phase 1 trial of 2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial is designed to evaluate the safety of 2510 in patients with solid tumors. It also aims to assess the efficacy of the treatment. Additionally, the study will examine the pharmacokinetics and pharmacodynamics of the drug.
07/02/2025 REGN Regeneron Pharmaceuticals 11:00 AM FDA Decision Lynozyfic™ (linvoseltamab-gcpt) To treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody. Approved FDA Accelerated Approval 11/30/-0001 11/30/-0001 Regeneron Pharmaceuticals, Inc. (REGN) announced that the U.S. Food and Drug Administration has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. These therapies include a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial.
06/30/2025 TAK Takeda 08:00 AM FDA Decision GAMMAGARD LIQUID ERC [immune globulin infusion (human)] Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency Approved FDA Approval 11/30/-0001 11/30/-0001 Takeda (TAK) announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC immune globulin infusion (human) with less than or equal to 2 µg/mL IgA in a 10% solution. It is the only ready-to-use liquid immunoglobulin therapy with low immunoglobulin A content. The therapy is approved as a replacement treatment for people two years of age and older with primary immunodeficiency.

After Hour Movers

Date Time Symbol Company Name Last Updated Close Price Change Percent Day Range 52Wk Range Sector / Industry dailyvolume marketcap news_link Catalyst News
06/16/2026 07:05 PM LNAI Lunai Bioworks Inc. 16-Jun 19:05 2.85 5.09 2.24 78.60 $2.56 ~ $2.92 $1.21 ~ $31.04 73.37 12.90
06/16/2026 09:29 AM VACH Voyager Acquisition Corp. 16-Jun 09:29 14.26 21.00 6.74 47.27 $14.26 ~ $21.57 $8.40 ~ $27.36 2.80 450.97
06/16/2026 07:05 PM MCRP Micropolis AI Robotics 16-Jun 19:05 2.16 3.09 0.93 43.06 $1.91 ~ $2.19 $0.69 ~ $4.62 138.85 75.36
06/16/2026 07:49 AM MLAC Mountain Lake Acquisition Corp. 16-Jun 07:49 0.98 1.29 0.31 31.63 $0.95 ~ $1.22 $0.96 ~ $10.69 2.57 30.37
06/16/2026 07:05 PM CRE Cre8 Enterprise Limited Class A Ord 16-Jun 19:05 3.27 4.18 0.91 27.83 $3.18 ~ $6.17 $1.68 ~ $102.18 21.90 6.59
06/16/2026 07:05 PM ONCO Onconetix, Inc. 16-Jun 19:05 1.08 1.29 0.21 19.44 $1.06 ~ $1.11 $0.91 ~ $270.00 93.93 360.00
06/16/2026 07:05 PM CREG Smart Powerr Corp. 16-Jun 19:05 2.07 2.46 0.39 18.84 $1.81 ~ $2.20 $1.62 ~ $34.99 320.40 4.75
06/16/2026 07:04 PM LZB La-Z-Boy Incorporated 16-Jun 19:04 35.14 41.21 6.07 17.27 $35.07 ~ $38.36 $29.03 ~ $41.06 803.53 1.45 La-Z-Boy Profit Climbs, Helped by New Stores
WSJ | 2026-06-16 16:53:00
La-Z-Boy ($LZB) Posts Q4 Higher EPS; Sees Q1 Revenue Growth
Catalyst picR | 2026-06-16 16:48:50
La-Z-Boy Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga | 2026-06-15 06:04:16
06/16/2026 07:05 PM NIVF NewGenIvf Group Limited 16-Jun 19:05 0.70 0.82 0.12 17.14 $0.60 ~ $1.04 $0.47 ~ $420.00 100.54 400.00
06/16/2026 06:59 PM NXGL NEXGEL, Inc. 16-Jun 18:59 0.53 0.61 0.08 15.09 $0.53 ~ $0.56 $0.48 ~ $2.89 101.50 4.90

After Hour Insights


© Catalyst picR 2025-26